Which chronic myeloproliferative disorder is treated with Imatinib mesylate (Gleevec), a drug that inhibits tyrosine kinase?
a. Polycythemia vera
b. Chronic myelogenous leukemia
c. Essential thrombocythemia
d. Primary myelofibrosis
ANS: B
Chronic myelogenous leukemia is effectively treated with Imatinib mesylate. This drug inhibits most of the transforming capability stemming from the tyrosine kinase (P210) activity of the bcr/abl fusion gene. This P210 fusion protein is not found in the other myeloproliferative disorders, so the drug is ineffective in these disorders.
You might also like to view...
A patient is being considered for participation in a pulmonary rehabilitation program. Which of the following test regimens would you recommend in order to ascertain the patient's cardiopul-monary status?
1. Cardiopulmonary exercise evaluation 2. Pulmonary function testing 3. Cardiac catheterization a. 2 and 3 only b. 1 and 2 only c. 1, 2, and 3 d. 1 and 3 only
Discuss gingival signs that may be evident when a patient uses an incorrect brushing and flossing technique
What will be an ideal response?
Ferrets do not have a very well-developed sense of ____________________
Fill in the blank(s) with correct word
A poison having destructive effects on the kidneys is a/an _____
Fill in the blank(s) with correct word